Craig Hattenback

“Mike, the comment that resiliency is part of the core now, can you just touch on some of the applications you've been able to accelerate this year, as well as any untapped opportunities you see on a longer-term basis on resiliency?”

“And great discussion around all the AI developments. Peter, from a macro perspective, you know, after a couple of volatile years, whether it was IRA, MFN pricing, tariffs, you know, the backdrop has steadied.”

“So John, it's now been kind of a couple quarters since you're realigned kind of the sales and go-to-market strategy. Just would love an update on kind of what's working to date and then just some of the milestones, the things to watch out for as you execute on that.”

“As you prepare to launch Migraine on a broader basis, are there any parallels to other product rollouts? So for example, you saw a yield expansion from programs in women's health that just provide kind of a look at the opportunity to drive yield expansion in 27 and beyond?”

“Peter, given you're furthest along on AI and kind of default CRM agents that launched back in December, curious kind of what the initial uptake is there. Is there anything you want to tie into the recent commercial summit?”